AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology
QINGDAO, China, April 27, 2026 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the commencement of its next-generation, proprietary Brain-Computer Interface (BCI) technology research and development...
EcoFlow Launches DELTA 3 Max Plus in Australia: Class-Leading 2kWh Portable Power Station with 3000W Output
Anderson-ready portable power station with built-in high-current DC output for direct 4WD and caravan integration SYDNEY, March 2, 2026 /PRNewswire/ -- EcoFlow, a leader in portable power and renewable energy solutions, today launches the DELTA 3...
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously...
